Mateon Therapeutics Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$0.07 |
Market Cap |
$8.08 M |
Shares Outstanding |
82.1 M |
Public Float |
40.21 M |
Address |
701 Gateway Boulevard South San Francisco California 94080 United States |
Employees | - |
Website | http://www.mateon.com |
Updated | 07/08/2019 |
Mateon Therapeutics, Inc. operates as a clinical stage biopharmaceutical company which develops small molecule injectable drugs for the treatment of cancer. The firm develops OXi4503 for the treatment of acute myeloid leukemia. The OXi4503 has dual mechanism of action which causes the release of leukemic stem cells from the bone marrow and enables their destruction. |